Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q1 2020 · 10-Q
Revenue—
Net Income-$16.60M-$16.60MN/M vs Q1 2019 EPS Diluted-$0.62-$0.62N/M vs Q1 2019 Operating Income-$8,184,026N/M Operating Cash Flow-$6,673,676N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Feb 14, 2020 · 45 d after period end